Literature DB >> 24360324

An algorithm for treating chronic urticaria with omalizumab: dose interval should be individualized.

Pınar Uysal1, Esben Eller1, Charlotte G Mortz1, Carsten Bindslev-Jensen2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24360324     DOI： 10.1016/j.jaci.2013.10.015

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN： 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  10 in total

Review 1.  Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients With Chronic Idiopathic (Spontaneous) Urticaria: A Meta-analysis of "Real-world" Evidence.

Authors:  Michael D Tharp; Jonathan A Bernstein; Abhishek Kavati; Benjamin Ortiz; Karen MacDonald; Kris Denhaerynck; Ivo Abraham; Christopher S Lee
Journal:  JAMA Dermatol       Date:  2019-01-01       Impact factor: 10.282

2.  Effective treatment of different phenotypes of chronic urticaria with omalizumab: Case reports and review of literature.

Authors:  A Kasperska-Zajac; J Jarząb; A Żerdzińska; K Bąk; A Grzanka
Journal:  Int J Immunopathol Pharmacol       Date:  2016-01-04       Impact factor: 3.219

Review 3.  An Overview of Off-Label Use of Humanized Monoclonal Antibodies in Paediatrics.

Authors:  Roberto Bernardini; Gaia Toschi Vespasiani; Arianna Giannetti
Journal:  Medicina (Kaunas)       Date:  2022-04-29       Impact factor: 2.948

Review 4.  Chronic spontaneous urticaria: latest developments in aetiology, diagnosis and therapy.

Authors:  Christian Vestergaard; Mette Deleuran
Journal:  Ther Adv Chronic Dis       Date:  2015-11       Impact factor: 5.091

5.  Safety and effectiveness of omalizumab for the treatment of chronic urticaria in pediatric patients.

Authors:  Coco Dekkers; Mehran Alizadeh Aghdam; Marlies de Graaf; André C Knulst; Yolanda Meijer; Juul M P A van den Reek; Marike B Stadermann; Heike Röckmann
Journal:  Pediatr Allergy Immunol       Date:  2021-01-18       Impact factor: 6.377

6.  Long-term treatment of refractory severe chronic urticaria by omalizumab: analysis of two cases.

Authors:  Irene Fiorino; Filomena Loconte; Anna Simona Rucco; Andrea Nico; Maddalena Vacca; Elisabetta Damiani; Eustachio Nettis; Maria Filomena Caiaffa; Luigi Macchia
Journal:  Postepy Dermatol Alergol       Date:  2014-10-22       Impact factor: 1.837

7.  High-dose non-sedating antihistamines are used insufficiently in chronic urticaria patients treated with omalizumab.

Authors:  Hanne Madsen; Charlotte G Mortz; Carsten Bindslev-Jensen; Mette Reilev; Jesper Hallas; Daniel P Henriksen
Journal:  Clin Transl Allergy       Date:  2021-12-11       Impact factor: 5.871

8.  Omalizumab-A Review.

Authors:  Kiran Godse; Aayushi Mehta; Sharmila Patil; Manjyot Gautam; Nitin Nadkarni
Journal:  Indian J Dermatol       Date:  2015 Jul-Aug       Impact factor: 1.494

9.  Omalizumab for chronic urticaria in Latin America.

Authors:  Paul Wilches; Paola Wilches; Juan Carlos Calderon; Annia Cherrez; Ivan Cherrez Ojeda
Journal:  World Allergy Organ J       Date:  2016-11-23       Impact factor: 4.084

Review 10.  Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence.

Authors:  Martin Metz; Zahava Vadasz; Emek Kocatürk; Ana M Giménez-Arnau
Journal:  Clin Rev Allergy Immunol       Date:  2020-08       Impact factor: 8.667
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.